Creative Biolabs is a CRO company that can leverage natural T cell activation pathways to design novel T cell antigen connector (TAC) elements and translate them into a new generation of cell therapies. We have created a flexible, scalable, broad, and transformative platform for cell therapy.
Discover novel tumor-specific TACs
Produce TACs of high affinity and specificity
Target a wide variety of tumor-assoicated antigens
Fig.1 Features of TAC Platform. (Creative Biolabs)
The combination of gene-engineered methods and chimeric antigen receptor (CAR) T cell therapy has developed a heartening road via redirecting T cells to target tumor antigens more effectively to perform the anti-tumor function of T cells. As a first-in-class service provider of immunotherapy development, we have established an advanced T Cell Antigen Connector (TAC) technology platform to assist in the design and development of novel T-cell therapies that are safer and more effective than current CAR-T therapy.
Fig.2 The Detection of TAC-T Cells Kill Malignant T Cells. (Creative Biolabs)
In the past few years of studies, the effectiveness of CAR-T in the treatment of liquid tumors is very limited, and the efficacy in solid tumors has not been proven. Therefore, we are advancing a novel TAC-mediated cell therapy designed to overcome these known challenges in antigen heterogeneity, recognition, trafficking, exhaustion, and survival and offer several potential advantages for treating hematologic cancers and solid tumors:
In our platform, TAC construct co-opts the natural T cell signaling pathways and is independent of the major histocompatibility complex (MHC), demonstrating strong efficacy in both solid and liquid tumors with an improved safety profile compared to current chimeric antigen receptor (CAR)-T approaches. Nowadays, we focus on many different cancers as well as autoimmune diseases, targeting a wide range of tumor-specific antigens or tumor-associated antigens.
Fig.3 The Tumor Weight Was Significantly Decreased in BCMA-Treated Mice Models. (Creative Biolabs)
Fig.4 BCMA TAC-T Cells Can Block The Growth of MM1S Xenograft Tumors. (Creative Biolabs)
Extended Access
Creative Biolabs is committed to developing next-generation cellular therapies for a variety of hematologic malignancies and solid tumors. With the continuous success of TAC models for different diseases, we can provide a broader therapeutic landscape for diseases, not limited to tumors.
If you have any special needs in TAC design and development solutions or be interested in learning more about Creative Biolabs’ TAC services, please feel free to contact us for more details.
For Research Use Only
